

PHARMACEUTICAL TURNOVER
Three months ended 31st March 2005

	Total			USA			Europe			International		
	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%	£m	CER%	£%
RESPIRATORY	1,198	12	11	591	12	8	416	10	12	191	18	16
<i>Seretide/Advair</i>	690	22	20	380	25	20	251	19	21	59	11	11
<i>Flixotide/Flovent</i>	154	-	-	61	1	(3)	49	(4)	2	44	4	2
<i>Serevent</i>	79	(11)	(11)	24	(30)	(33)	40	(7)	(5)	15	30	36
<i>Flixonase/Flonase</i>	171	12	9	120	-	(5)	14	(2)	-	37	>100	>100
CENTRAL NERVOUS SYSTEM	758	(15)	(17)	478	(18)	(22)	184	(7)	(5)	96	(11)	(12)
<i>Seroxat/Paxil</i>	163	(43)	(44)	50	(64)	(66)	52	(29)	(27)	61	(13)	(15)
<i>Paxil IR</i>	122	(36)	(36)	11	(76)	(77)	52	(29)	(27)	59	(15)	(17)
<i>Paxil CR</i>	41	(57)	(59)	39	(59)	(61)	-	-	-	2	74	100
<i>Wellbutrin</i>	163	(23)	(26)	160	(23)	(26)	-	-	-	3	(28)	(25)
<i>Wellbutrin IR, SR</i>	32	(75)	(76)	30	(76)	(77)	-	-	-	2	(41)	(50)
<i>Wellbutrin XL</i>	131	56	49	130	56	48	-	-	-	1	88	-
<i>Imigran/Imitrex</i>	167	-	(3)	123	2	(2)	33	(6)	(6)	11	(1)	-
<i>Lamictal</i>	195	30	27	120	38	32	63	20	24	12	9	9
<i>Requip</i>	30	15	15	13	14	8	15	16	15	2	13	100
ANTI-VIRALS	603	9	7	301	16	11	186	-	2	116	8	7
HIV	363	6	4	178	8	3	144	1	3	41	13	14
<i>Combivir</i>	140	2	1	68	4	-	56	(2)	-	16	4	7
<i>Trizivir</i>	74	(7)	(9)	39	(4)	(9)	31	(10)	(9)	4	(6)	-
<i>Epivir</i>	66	(6)	(7)	25	(20)	(24)	30	2	3	11	18	22
<i>Ziagen</i>	33	(12)	(13)	13	(24)	(28)	14	(4)	(7)	6	14	20
<i>Retrovir</i>	11	8	10	4	6	-	4	(7)	-	3	40	50
<i>Agenerase, Lexiva</i>	22	>100	>100	14	>100	>100	7	>100	>100	1	>100	>100
<i>Epzicom/Kivexa</i>	17	-	-	15	-	-	2	-	-	-	-	-
Herpes	197	16	13	114	33	28	36	(4)	(3)	47	1	(2)
<i>Valtrex</i>	164	28	23	112	36	30	25	13	14	27	11	8
<i>Zovirax</i>	33	(20)	(20)	2	(51)	(33)	11	(29)	(27)	20	(9)	(13)
<i>Zeffix</i>	29	-	(3)	3	7	-	4	(4)	(20)	22	(1)	-
ANTI-BACTERIALS	417	(1)	(1)	76	(29)	(32)	222	13	17	119	1	(2)
<i>Augmentin</i>	192	(6)	(6)	46	(39)	(41)	98	16	20	48	13	9
<i>Augmentin IR</i>	154	10	11	12	(18)	(20)	95	13	17	47	13	9
<i>Augmentin ES, XR</i>	38	(40)	(41)	34	(43)	(46)	3	>100	>100	1	(6)	-
<i>Zinnat/Ceftin</i>	62	3	5	3	(2)	(25)	42	10	14	17	(10)	(6)
METABOLIC	319	22	19	215	21	16	40	31	33	64	20	19
<i>Avandia, Avandamet</i>	287	25	21	215	21	16	32	53	52	40	31	29
VACCINES	248	3	4	54	2	(2)	114	10	14	80	(4)	(5)
Hepatitis	94	4	4	26	(13)	(16)	48	13	14	20	13	18
<i>Infanrix/Pediarix</i>	83	9	9	28	20	17	40	12	14	15	(13)	(12)
<i>Rotarix</i>	1	-	-	-	-	-	-	-	-	1	-	-
ONCOLOGY AND EMESIS	235	9	6	171	12	7	43	-	2	21	6	5
<i>Zofran</i>	189	8	5	139	10	5	33	(1)	3	17	6	6
<i>Hycamtin</i>	25	7	4	17	10	6	7	-	-	1	4	-
CARDIOVASCULAR AND UROGENITAL	310	57	55	176	43	36	103	>100	>100	31	39	41
<i>Coreg</i>	135	50	44	133	52	46	-	-	-	2	(29)	(33)
<i>Levitra</i>	10	(39)	(41)	9	(12)	(18)	1	(79)	(80)	-	-	-
<i>Avodart</i>	26	>100	>100	12	>100	100	12	>100	>100	2	-	-
<i>Arixtra</i>	4	-	-	2	-	-	2	-	-	-	-	-
<i>Fraxiparine</i>	52	-	-	-	-	-	45	-	-	7	-	-
<i>Vesicare</i>	3	-	-	3	-	-	-	-	-	-	-	-
OTHER	251	(2)	(3)	17	(19)	(23)	80	2	4	154	(2)	(3)
<i>Zantac</i>	59	(13)	(13)	13	(19)	(24)	16	(18)	(20)	30	(6)	(3)
	4,339	6	4	2,079	4	(1)	1,388	10	12	872	5	4

INCOME STATEMENT
Three months ended 31st March 2005

	Q1 2005 £m	Q1 2004 £m	Growth* CER%	£%
Turnover:				
Pharmaceuticals	4,339	4,168	6	4
Consumer Healthcare	697	687	2	1
TURNOVER	5,036	4,855	5	4
Cost of sales	(1,127)	(1,035)	9	9
Gross profit	3,909	3,820	4	2
Selling, general and administration	(1,645)	(1,725)	(3)	(5)
Research and development	(663)	(659)	2	1
Other operating income	146	57		
Operating profit:				
Pharmaceuticals	1,626	1,395	18	17
Consumer Healthcare	121	98	23	23
OPERATING PROFIT	1,747	1,493	18	17
Finance income	49	43		
Finance expense	(98)	(84)		
Share of after tax profits of joint ventures and associates	13	14		
PROFIT BEFORE TAXATION	1,711	1,466	18	17
Taxation	(488)	(406)		
<i>Tax rate %</i>	28.5%	27.7%		
PROFIT AFTER TAXATION FOR THE PERIOD	1,223	1,060	17	15
Profit attributable to minority interests	21	23		
Profit attributable to shareholders	1,202	1,037	17	16
EARNINGS PER SHARE	21.1p	18.0p	19	17
Diluted earnings per share	21.0p	18.0p		

CONSUMER HEALTHCARE TURNOVER
Three months ended 31st March 2005

	£m	Growth CER%	£%
Over-the-counter medicines	343	5	3
Analgesics	84	3	4
Dermatological	39	(7)	(7)
Gastrointestinal	58	2	(2)
Respiratory tract	38	12	12
Smoking control	83	17	14
Natural wellness support	33	(4)	(3)
Oral care	219	(1)	(1)
Nutritional healthcare	135	1	-
Total	697	2	1